Abstract
Temazepam, 7.5 mg was evaluated in the sleep laboratory in 8 elderly insomniacs, using a 14-night protocol (4 placebo-baseline nights, 7 drug nights, and 3 placebo-withdrawal nights). With short-term use temazepam was found to be effective, producing a significant improvement in total wake time from baseline (100 vs. 145 min). With continued drug administration, total wake time remained below baseline but not significantly so (125 vs. 145 min). During drug administration, there were no major CNS and behavioral adverse effects reported such as daytime sedation, memory impairment or hyperexcitability (daytime anxiety). Following drug withdrawal, there was no significant increase in wakefulness, i.e., no rebound insomnia (150 vs. 145 min).
In summary, temazepam, 7.5 mg is effective in elderly subjects with short-term use and has a minimum of adverse effects. Use of hypnotic drugs is an adjunctive therapy which should be for a short-term period with subsequent short-term intermittent use as needed. Because of its low propensity for producing rebound insomnia, temazepam can be effectively used in this manner.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Monjan AA (1990) Sleep disorders of older people: report of a consensus conference. Hosp Community Psychiatry 41: 743–744
German PS, Burton LC (1989) Medication and the elderly. J Aging Health 1: 4–34
Morgan K, Dallosso H, Ebrahim S, Arie T, Fentem PH (1988) Prevalence, frequency, and duration of hypnotic drug use among the elderly living at home. Br Med J 296: 601–602
Avorn J, Gurwitz J (1990) Principles of pharmacology. In: Cassel CK, Riesenberg DE, Sorensen LB, Walsh JR (eds) Geriatric medicine, 2nd edn. Springer, Berlin Heidelberg New York, pp 66–77
Divoll M, Greenblatt DJ, Harmatz JS, Shader RI (1981) Effect of age and gender on disposition of temazepam. J Pharm Sci 70: 1104–1107
Bixler EO, Kales A (1985) Clinical laboratory evaluation of hypnotic drugs. In: McMahon FG (ed) Principles and techniques of human research and therapeutics: selected topics, vol II. Futura Publishing, Mount Kisco New York, pp 153–189
Kales A, Kales JD, Bixler EO, Scharf M (1975) Methodology of sleep laboratory drug evaluations. In: Kagan F, Harwood T, Rickels K, Rudzik A, Sorer H (eds) Hypnotics: methods of development and evaluation. Spectrum, New York, pp 109–120
Kales A, Scharf MB, Soldatos CR, Bixler EO (1979) Clinical evaluation of hypnotic drugs: contributions from sleep laboratory studies. J Clin Pharmacol 19: 329–336
Soldatos CR, Kales A (1979) Role of the sleep laboratory in the evaluation of hypnotic drugs. In: Priest RG, Fletcher A, Ward J (eds) Sleep research. MTP Press, Lancaster England, pp 181–196
Agnew HW, Webb WB, Williams RL (1966) The first night effect: an EEG study of sleep. Psychophysiology 2: 263–266
Scharf MB, Kales A, Bixler EO (1975) Readaptation to the sleep laboratory in insomniac subjects. Psychophysiology 12: 412–415
Rechtschaffen A, Kales A (eds) (1968) A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects (NIH publication 204), Government Printing Office, Washington DC
Spielberger CD, Gorsuch RL, Lushene RE (1970) Manual for the State-Trait Anxiety Inventory (self-evaluation questionnaire). Consultant Psychologists Press, Palo Alto
Dunn OJ (1961) Multiple comparisons among means. J Am Stat Assoc 56: 52
Bixler EO, Kales A, Soldatos CR, Scharf MB, Kales JD (1978) Effectiveness of temazepam with short-, intermediate-, and long-term use: sleep laboratory evaluation. J Clin Pharmacol 18: 110–118
Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby JA, Kales JD (1986) Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal. Clin Pharmacol Ther 39: 345–352
Kales A, Manfredi RL, Vgontzas A, Bixler EO, Vela-Bueno A, Fee EC (1991) Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharm Ther 49: 468–476
Bixler EO, Kales A, Manfredi RL, Vgontzas AN, Tyson KL, Kales JD (1991) Triazolam: prevalence, rate and degree of next-day memory impairment. Lancet 337: 827–831
Scharf MB, Fletcher K, Graham JP (1988) Comparative amnestic effects of benzodiazepine hypnotic agents. J Clin Psychiatry 49: 134–137
Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI (1989) Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam, and triazolam. Arch Gen Psychiatry 46: 326–332
Kales A, Kales JD, Bixler EO, Scharf MB, Russek E (1976) Hypnotic efficacy of triazolam: sleep laboratory evaluation of intermediate-term effectiveness. J Clin Pharmacol 6: 399–406
Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Niklaus DE, Manfredi RL (1986) Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam. Clin Pharmacol Ther 40: 378–386
Kales A, Bixler EO, Soldatos CR, Mitsky DJ, Kales JD (1982) Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia. J Clin Pharmacol 22: 520–530
Kales A, Soldatos CR, Bixler EO, Goff PJ, Vela-Bueno A (1983) Midazolam: dose-response studies of effectiveness and rebound insomnia. Pharmacol 26: 138–149
Scharf MB, Sachais BA, Mayleben DW, Fletcher K, Jennings SW (1990) A polysomnographic comparison of temazepam 15 and 30 mg with triazolam 0.125 and 0.25 mg in chronic insomnia. Curr Ther Res 48: 555–567
Mitler MM, Carskadon MA, Phillips RL, Sterling WR, Zarcone VP, Spiegel R, Guilleminault C, Dement WC (1979) Hypnotic efficacy of temazepam: a long-term sleep laboratory evaluation. J Clin Pharmacol 8: 635–685
Roehrs T, Lamphere J, Paxton C, Wittig R, Zorick F, Roth T (1984) Temazepam's efficacy in patients with sleep onset insomnia. Br J Clin Pharmacol 17: 691–696
Kales A (1991) An overview of safety problems of triazolam. Int Drug Ther Newsl 26: 25–28
Kales A, Vgontzas AN (1990) Not all benzodiazepines are alike. In: Stefanis CN, Rabavilas AD, Soldatos CR (eds) Psychiatry: a world perspective, vol 3. Elsevier, Amsterdam, pp 379–84
File SE, Pello S (1985) Triazolobenzodiazepines antagonize the effects of anxiogenic drugs mediated at three different central nervous system sites. Neurosci Lett 61: 115–119
Kalogeras KT, Calogero AE, Kuribayiashi T, Khan I, Gallucci WT, Kling MA, Chrousos GP, Gold PW (1990) In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. J Clin Endocrin Metab 70: 1462–1471
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vgontzas, A.N., Kales, A., Bixler, E.O. et al. Temazepam 7.5 mg: effects on sleep in elderly insomniacs. Eur J Clin Pharmacol 46, 209–213 (1994). https://doi.org/10.1007/BF00192550
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00192550